FDA Approves Potentially Groundbreaking Schizophrenia Drug
On Thursday, the Food and Drug Administration approved Cobenfy, a drug from Bristol Myers Squibb—the first truly novel ...
Schizophrenia Treatment Revolution: FDA Approves Bristol Myers Squibb's Cobenfy As First New Class Of Treatment In More Than 3 Decades
Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults. Bristol-Myers added the ...
Bristol Cobenfy approval draws optimism from Street, though with caveats
The FDA approval of Bristol Myers Squibb's Cobenfy for schizophrenia could revolutionize treatment, but faces a competitive ...
FDA Approves the First New Schizophrenia Drug in Decades
Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...
Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)
Bristol-Myers Squibb's acquisition of Karuna and FDA approval of Cobenfy signal growth potential, with focus on driving ...
FDA approves Cobenfy: A breakthrough Schizophrenia treatment after decades
The US FDA has approved Bristol Myers Squibb’s new oral medicine, Cobenfy, for treating schizophrenia in adults. This ...
Bristol Myers gets FDA approval for Cobenfy to treat Schizophrenia
The US FDA has approved Bristol Myers Squibb’s oral medicine, Cobenfy, for treating schizophrenia in adults. This is the ...
Medscape4h
FDA OKs First-in-Class Antipsychotic for Schizophrenia
The FDA has approved a first-in-class antipsychotic that targets cholinergic receptors without blocking dopamine receptors.
C&EN19h
FDA approves Cobenfy, a first-in-class schizophrenia drug
But Cobenfy can still cause side effects, the most common of which are gastrointestinal in nature like nausea and vomiting, diarrhea, indigestion, and constipation. The FDA says people with known ...
HealthDay on MSN2h
FDA Approves New Kind of Drug for Schizophrenia
The first new type of medication in decades to help fight against schizophrenia was approved on Thursday by the U.S. Food and ...
The FDA just approved Bristol Myers Squibb's groundbreaking schizophrenia treatment
The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated ...
FiercePharma19h
Bristol Myers Squibb's Karuna buyout pays off with FDA approval for novel schizophrenia med Cobenfy
After decades of stagnation in the schizophrenia field, Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has ...